1. Advancing a Vision for Regulatory Science Training
2. EC(1999).European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products(Official Journal of the European Communities L 018 22 January 2000).
3. EC(2000).European Commission. Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’(Official Journal of the European Communities L 103 28 April 2000).
4. EMA European Medicines Agency(2017).Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07 Rev. 1.https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐strategies‐identify‐mitigate‐risks‐first‐human‐early‐clinical‐trials‐investigational_en.pdf(12 October 2021).
5. EMA European Medicines Agency(2020).Paediatric medicines: overview.https://www.ema.europa.eu/en/human‐regulatory/overview/paediatric‐medicines‐overview(12 October 2021).